Table 5.

The association of TNFR2 and hsCRP with incident CKD stage 3 in a logistic regression model with and without adjusting for baseline GFR

CKD Stage 3 (<60 ml/min per 1.73 m2)Adjusted for Sex and Baseline Age, Weight, and HeightAdjusted for Sex and Baseline Age Weight, Height, and mGFR/eGFR
Odds Ratio95% CIP ValueOdds Ratio95% CIP Value
 mGFR1.320.59 to 2.930.500.580.19 to 1.740.33
 eGFRcre1.980.88 to 4.460.101.450.41 to 5.090.56
 eGFRcys5.432.18 to 13.5<0.0010.850.19 to 3.770.83
 eGFRcrecys2.650.91 to 7.710.070.460.06 to 3.430.45
 mGFR1.041.00 to to 1.090.02
 eGFRcre1.020.96 to 1.080.571.030.96 to 1.110.36
 eGFRcys1.030.96 to 1.100.471.010.94 to 1.100.74
 eGFRcrecys1.020.91 to 1.130.831.020.91 to 1.150.72
  • The Renal Iohexol-Clearance Survey Follow-Up Study. The odds ratios represent 1 SD higher TNFR2 and 1 mg/L higher hsCRP. Each row represents separate logistic regression models with CKD stage 3 (yes/no) as a dependent variable. TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; mGFR, measured GFR; 95% CI, 95% confidence interval; eGFRcre, estimated GFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.